- Biomerica has entered into a Master Services Agreement with a confidential life sciences company to develop proprietary in vitro diagnostic assays, with initial contract development fees exceeding $1.75 million.
- The three-year agreement will be executed at Biomerica’s FDA-licensed and ISO 13485-certified facility in Irvine, California, with revenue recognized as project milestones are completed.
Biomerica, Inc. has signed a Master Services Agreement (MSA) with an undisclosed life sciences company to develop proprietary in vitro diagnostic (IVD) assays. The agreement includes an initial contract development target fee of more than $1.75 million, which will be earned through multiple Statements of Work conducted under the MSA.
According to the company, the agreement has an initial term of three years with automatic one-year renewals. All development activities will be carried out at Biomerica’s FDA-licensed, ISO 13485-certified facility in Irvine, California. Revenue from the project will be recognized as individual milestones and deliverables are completed and accepted.
Biomerica stated that the engagement builds on its ELISA-based assay development capabilities, which also support its inFoods IBS technology platform. The company said the CDMO project will be completed using its existing research team, equipment, and infrastructure, with minimal additional capital investment required.
The company noted that the agreement provides an additional revenue stream while maintaining its focus on commercializing the inFoods IBS platform. Biomerica also stated that the partner selected the company following a competitive evaluation involving multiple CDMO organizations.
“The $1.75 million in initial development fees provides near-term revenue visibility and demonstrates that the capabilities Biomerica has built over more than 40 years — in assay development, regulatory compliance, and IVD manufacturing — have direct commercial value beyond our own product pipeline.”
Zack Irani, Chief Executive Officer of Biomerica
